What is Migalastat: Uses, Dosage, Side Effects and More

Migalastat is a prescription medication specifically designed to treat Fabry disease, a rare genetic condition that affects how your body processes certain fats. This oral medication works as a "pharmacological chaperone," helping your body's enzymes function better when they're not working properly due to genetic mutations.

If you or a loved one has been diagnosed with Fabry disease, you might feel overwhelmed by the medical terminology and treatment options. Understanding how migalastat works can help you feel more confident about your treatment journey and what to expect along the way.

What is Migalastat?

Migalastat is a small molecule drug that belongs to a class called pharmacological chaperones. Think of it as a helper that assists your body's natural enzymes in doing their job more effectively.

Specifically, migalastat helps stabilize an enzyme called alpha-galactosidase A, which is deficient or not working properly in people with Fabry disease. When this enzyme doesn't function correctly, certain fatty substances build up in your cells, leading to the symptoms of Fabry disease.

The medication comes in capsule form and is taken by mouth. It's marketed under the brand name Galafold and was approved by the FDA in 2018 for treating adults with confirmed Fabry disease.

What is Migalastat Used For?

Migalastat is used exclusively to treat Fabry disease in adults who have specific genetic mutations that respond to this type of therapy. Fabry disease is a rare inherited disorder that affects multiple organs in your body.

Your doctor will need to confirm through genetic testing that you have the right type of Fabry disease mutation before prescribing migalastat. Not all genetic variations of Fabry disease will respond to this medication, which is why testing is so important.

The medication helps reduce the buildup of fatty substances in your cells, which can potentially slow down or prevent some of the complications associated with Fabry disease. These complications can affect your heart, kidneys, nervous system, and skin.

How Does Migalastat Work?

Migalastat works by binding to and stabilizing the alpha-galactosidase A enzyme in your cells. This enzyme is responsible for breaking down a fatty substance called globotriaosylceramide (GL-3).

When you have Fabry disease, your body either doesn't make enough of this enzyme or makes a version that doesn't work properly. Migalastat acts like a molecular scaffold, helping the enzyme maintain its proper shape and function more effectively.

This is considered a moderately strong medication in terms of its specific action, but it's generally well-tolerated by most people. The drug needs to reach certain levels in your bloodstream to be effective, which is why consistent dosing is important.

How Should I Take Migalastat?

Take migalastat exactly as prescribed by your doctor, typically once every other day at the same time. The standard dose is usually 123 mg, but your doctor will determine the right amount for your specific situation.

You should take migalastat on an empty stomach, at least 2 hours before or 2 hours after eating any food. This is important because food can interfere with how well your body absorbs the medication.

Swallow the capsule whole with a glass of water. Don't crush, chew, or open the capsule, as this can affect how the medication works. Try to take it at the same time each dosing day to help you remember and maintain consistent levels in your body.

If you're taking migalastat, avoid drinking large amounts of tea, coffee, or other caffeinated beverages around the time you take your dose, as these might interfere with absorption.

How Long Should I Take Migalastat For?

Migalastat is typically a long-term treatment that you'll need to take for an extended period, possibly for life. Since Fabry disease is a chronic genetic condition, ongoing treatment is usually necessary to maintain the benefits.

Your doctor will monitor your response to the medication through regular blood tests and other assessments. They'll track markers that show how well the treatment is working and whether your Fabry disease symptoms are improving or stabilizing.

The timeline for seeing benefits can vary from person to person. Some people may notice improvements in certain symptoms within a few months, while others may take longer to experience the full effects of treatment.

What Are the Side Effects of Migalastat?

Like all medications, migalastat can cause side effects, though not everyone experiences them. Most side effects are mild to moderate and tend to improve as your body adjusts to the medication.

The most common side effects that people experience include headache, nausea, and urinary tract infections. These typically occur in the first few weeks of treatment and often become less noticeable over time.

Here are the side effects you might experience, grouped by how common they are:

Common side effects (affecting more than 1 in 10 people):

• Headache
• Nausea
• Urinary tract infections
• Upper respiratory tract infections

Less common side effects (affecting 1 in 10 to 1 in 100 people):

• Dizziness
• Fatigue
• Diarrhea
• Constipation
• Abdominal pain
• Muscle spasms
• Back pain

Rare side effects (affecting fewer than 1 in 100 people):

• Severe allergic reactions
• Significant changes in kidney function
• Unusual changes in heart rhythm
• Severe digestive problems

Most people tolerate migalastat well, and serious side effects are uncommon. However, it's important to report any concerning symptoms to your healthcare provider, especially if they persist or worsen over time.

Who Should Not Take Migalastat?

Migalastat isn't suitable for everyone with Fabry disease. Your doctor will need to confirm through genetic testing that you have amenable mutations before prescribing this medication.

You should not take migalastat if you're allergic to the medication or any of its ingredients. Tell your doctor about any previous allergic reactions you've had to medications.

People with severe kidney disease may need special monitoring or dose adjustments, as the medication is processed through the kidneys. Your doctor will check your kidney function regularly if you're taking migalastat.

If you're pregnant or planning to become pregnant, discuss this with your doctor. While there's limited data on migalastat use during pregnancy, your doctor will weigh the potential benefits against any risks.

Migalastat Brand Names

Migalastat is primarily marketed under the brand name Galafold. This is the most common name you'll see on prescriptions and medication bottles.

The medication is manufactured by Amicus Therapeutics and is available in most countries where it has regulatory approval. Generic versions of migalastat are not currently available, as the medication is still under patent protection.

When discussing your treatment with healthcare providers or pharmacists, you can refer to it by either name - migalastat or Galafold - and they'll understand what medication you're talking about.

Migalastat Alternatives

For people with Fabry disease, the main alternative to migalastat is enzyme replacement therapy (ERT) using medications like agalsidase alfa or agalsidase beta. These are given as intravenous infusions rather than oral capsules.

The choice between migalastat and ERT depends on several factors, including your specific genetic mutation, how well you tolerate each treatment, and your personal preferences about treatment methods.

Some people may switch between treatments or use them in combination, depending on their response and any side effects they experience. Your doctor will help determine which approach is best for your individual situation.

There's also ongoing research into other potential treatments for Fabry disease, including gene therapy and other novel approaches, though these are still in experimental stages.

Is Migalastat Better Than Enzyme Replacement Therapy?

Whether migalastat is better than enzyme replacement therapy depends on your individual circumstances and genetic makeup. Both treatments can be effective for managing Fabry disease, but they work in different ways.

Migalastat offers the convenience of oral dosing every other day, while enzyme replacement therapy requires intravenous infusions every two weeks. Many people prefer the convenience of taking a pill at home rather than visiting a healthcare facility for infusions.

However, migalastat only works for people with specific genetic mutations that are "amenable" to this type of treatment. If your genetic testing shows you don't have these mutations, enzyme replacement therapy would be the better option.

Studies have shown that both treatments can be effective in reducing the buildup of fatty substances in cells and improving some symptoms of Fabry disease. Your doctor will consider your genetic profile, lifestyle preferences, and overall health when recommending the best treatment for you.